Key Insights

Highlights

Success Rate

89% trial completion (above average)

Published Results

13 trials with published results (32%)

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 27/100

Termination Rate

9.8%

4 terminated out of 41 trials

Success Rate

88.9%

+2.3% vs benchmark

Late-Stage Pipeline

20%

8 trials in Phase 3/4

Results Transparency

41%

13 of 32 completed with results

Key Signals

13 with results89% success

Data Visualizations

Phase Distribution

31Total
Not Applicable (4)
P 1 (8)
P 2 (11)
P 3 (7)
P 4 (1)

Trial Status

Completed32
Unknown4
Terminated4
Not Yet Recruiting1

Trial Success Rate

88.9%

Benchmark: 86.5%

Based on 32 completed trials

Clinical Trials (41)

Showing 20 of 20 trials
NCT04365101Phase 1Terminated

Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19

NCT04376034Phase 3Completed

Convalescent Plasma Collection and Treatment in Pediatrics and Adults

NCT05422326Phase 2Completed

A Study to Evaluate Safety and Immunogenicity of One or Two Booster Vaccinations With H5N6 Influenza Vaccine in Adults Primed With H5N1 Influenza Vaccine or Unprimed

NCT07543458Phase 3Not Yet Recruiting

Therapeutics for Moderate and Severe Dengue

NCT07254052CompletedPrimary

Effectiveness of Ammonium Chloride in Reducing Viral Load

NCT05284097Phase 2Completed

Ad26.ZEBOV, MVA-BN-Filo Vaccination in Children and Adults Previously Vaccinated With Control in the EBOVAC-Salone Study

NCT04772469Not ApplicableCompleted

Self-Test Strategies and Linkage Incentives to Improve ART and PrEP Uptake in Men

NCT04380701Phase 1Completed

A Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-19 in Healthy and Immunocompromised Adults

NCT04476979Phase 2Completed

Comparison of Tocilizumab Plus Dexamethasone vs. Dexamethasone for Patients With Covid-19

NCT02613403Phase 2Terminated

Efficacy and Safety of Grazoprevir (+) Uprifosbuvir (+) Ruzasvir (MK-3682B) (MK-5172 + MK-3682 + MK-8408) Fixed Dose Combination in Chronic HCV Participants Failing Prior Antiviral Treatment (MK-3682-021)

NCT04664075Terminated

Predicting Severity and Disease Progression in Influenza-like Illness (Including COVID-19)

NCT03110770Phase 2Completed

VRC 705: A Zika Virus DNA Vaccine in Healthy Adults and Adolescents

NCT05065905Phase 1Completed

Study of Interferon-Gamma in the Complex Treatment of Patients Infected With HIV and Tuberculosis

NCT01791556Not ApplicableCompleted

Clinic-based ART Diagnostic Evaluation

NCT05307991Completed

Integrating Enhanced HIV PrEP Into a STI Clinic in Lilongwe

NCT03301051Phase 3Completed

Efficacy, Safety, and Immunogenicity of a Plant-Derived Quadrivalent Virus-Like Particles (VLPs) Influenza Vaccine in Adults

NCT03321968Phase 3Completed

Lot-to-lot Consistency of a Plant-Derived Quadrivalent Virus-Like Particles Influenza Vaccine in Healthy Adults

NCT03739112Phase 3Completed

Efficacy of a Plant-derived Quadrivalent Virus-like Particle (VLP) Vaccine in the Elderly

NCT04644484Phase 3Completed

A Phase III Clinical Study to Evaluate SYN023's Efficacy and Safety

NCT04367740Completed

ScreenNC, a Study to Determine the Number of Asymptomatic Individuals Who Have Antibodies to the Virus That Causes COVID-19

Scroll to load more

Research Network

Activity Timeline